Research Library

Precision psychiatry promises to more accurately diagnose and treat patients. Brain health experts call for European researchers, policymakers and industry to work together to advance the field and give Europe a competitive edge.

Breathtaking AI advances necessitate a new suite of brain science-inspired policies to build brain capital.

Stem cells have two unique properties that make them an appealing therapeutic tool for regenerative medicine: they can grow indefinitely and can differentiate into a wide variety of cell types, including those that form blood, bones, lungs, skin, and the brain.

Effective drug policy requires acceptance that, for better or worse, licit and illicit drug use is part of our world. The authors recommend several steps the federal government can take to facilitate more pragmatic and effective drug policy at all levels of government.

The drastic impact of the Covid-19 pandemic on organized crime in Mexico requires policymakers and law enforcement in the U.S. and Mexico to adapt their strategies, the authors write.

High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.

There is broad consensus in the medical and scientific community that substance abuse should be treated as a medical and public health problem, not a crime. The authors recommend a sensible pivot from failed policies of drug prohibition toward a realistic approach to drug use.

The human papillomavirus (HPV) affects over 80 million Americans, causing more than 40,000 cases of HPV-associated cancers in the U.S. In 2006, the FDA licensed the first HPV vaccine, which could help save thousands of lives; no cure for HPV currently exists. However, the political controversy raised by the vaccine has limited its acceptance and use. Such resistance potentially jeopardizes an opportunity to reduce cancer rates in Texas and the broader United States.

Marijuana decriminalization and legalization have gone past being a trend and are settling in as federal policy, writes nonresident fellow Gary Hale, a 31-year veteran of the Drug Enforcement Administration. This policy brief includes recommendations for how the DEA can adjust its policies to adopt a new paradigm on marijuana policy.